Table 4.
Summary of Published Data and the Present Study on the Association Between 18F-FDG PET/CT Metabolic Parameters and Clinical Outcome of Advanced EGFR-Mutated Lung Adenocarcinoma
| Author, Year | Pathology | No. of Patients | Metabolic Parameters Analyzed | Results | TKIs Used |
|---|---|---|---|---|---|
| Keam et al,36 2015 | ADC, NSCC NOS | 75 | SUVmax and TLG of all lesions | High whole-body TLG (third quartile) is significantly associated with PFS and OS. | Gefitinib |
| Wang et al,11 2016 | ADC | 91 | SUVmax and TLG of the primary tumor and target lesions* | High whole-body TLG of (>260) is significantly associated with PFS but not OS. | Gefitinib |
| Sing et al,35 2020 | ADC | 41 | SUVmax | High SUVmax (>12) independently associated with PFS. | Erlotinib, Gefitinib |
| Present study | ADC | 60 | SUVmax, MTV, and TLG of the primary tumor | High TLG and MTV of the primary tumor were independently associated with PFS and OS. | Gefintib, Erlotinib, Afatinib |
Note: *Target lesions were selected in accordance with the RECIST 1.1 criteria.
Abbreviations: TKIs, tyrosine kinase inhibitors; ADC, adenocarcinoma; NSCC NOS, non-small-cell carcinoma not otherwise specified, SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; PFS, progression-free survival; OS, overall survival.